CARDIOVASCULAR CORE
心血管核心
基本信息
- 批准号:7638639
- 负责人:
- 金额:$ 25.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-06-01 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:AerobicAnimalsAtherosclerosisBlood PressureBlood VesselsBlood flowCardiacCardiovascular DiseasesCardiovascular systemCaringChemistryComplications of Diabetes MellitusCreatinine clearance measurementDiabetes MellitusEchocardiographyElectrolytesExerciseFiltrationFunctional disorderGlycosylated HemoglobinHealthHemoglobinHistologyHumanIn VitroInvestigationKidneyKidney DiseasesLipidsMeasurementMetabolicMethodsModelingModificationMonitorMorbidity - disease rateMorphologyMusPatientsPerformancePhenotypePostoperative PeriodPurposeRangeRateRegulationRenal functionRestRiskScreening procedureSerumServicesStress EchocardiographyStrokeTechniquesTelemetryTestingUrineVasomotordiabetic cardiomyopathygenetic manipulationhemodynamicsindexingmortalitymouse modelresponsesize
项目摘要
Cardiovascular and renal complications, including atherosclerosis and lipid abnormalities, diabetic
cardiomyopathy, stroke and renal disease, comprise the major morbidity and mortality in diabetes. The
complications of diabetes mellitus in mice appear to be largely the same as in humans. The purpose of the
Cardiovascular Pathophysiology and Complications Core (CPCC) is to provide rapid, comprehensive, and
accurate screening for cardiovascular disease and complications of diabetes in mouse models. The mouse
phenotyping tests used by this Core are modeled after and directly translatable to tests used to assess
patients with diabetes. Core services include assessment of a) cardiac morphology and function, including
morphology, histology and echocardiography; b) vascular regulation, including resting measurement of blood
pressure and response to vasomotor perturbations; c) exercise capacity and metabolic function; d)
comprehensive renal function; e) microvascular function; and f) circulating markers of cardiovascular disease
including electrolytes, indices of renal function, glycated hemoglobin, and serum lipids. The range of
phenotyping tests performed by the CPCC allows for thorough investigation of the presence, correlation with,
and modification or amelioration of cardiovascular disease, as well as diabetic complications associated with
specific genetic manipulations in the mouse.
心血管和肾脏并发症,包括动脉粥样硬化和脂质异常,糖尿病
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Douglas E Vaughan其他文献
1007-182 Aldosterone and plasma renin activity influence plasma plasminogen activato inhibitor-1 levels in overweight subjects
- DOI:
10.1016/s0735-1097(04)91875-x - 发表时间:
2004-03-03 - 期刊:
- 影响因子:
- 作者:
James A.S Muldowney;Barbara C Roberts;Joseph W Covington;John A Schoenhard;Nancy J Brown;Douglas E Vaughan - 通讯作者:
Douglas E Vaughan
1064-181 Distinct signaling pathways mediate protease activated receptor-dependent endothelial exocytosis
- DOI:
10.1016/s0735-1097(04)91968-7 - 发表时间:
2004-03-03 - 期刊:
- 影响因子:
- 作者:
John H Cleator;Douglas E Vaughan;Heidi E Hamm - 通讯作者:
Heidi E Hamm
Douglas E Vaughan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Douglas E Vaughan', 18)}}的其他基金
Evolutionary Advantage of Heterozygous PAI-1 Deficiency in Humans
人类杂合 PAI-1 缺陷的进化优势
- 批准号:
10686583 - 财政年份:2022
- 资助金额:
$ 25.66万 - 项目类别:
Spontaneous cardiac fibrosis in PAI-1-deficient mice and men: A rare mutation informs a common molecular pathophysiology
PAI-1 缺陷小鼠和男性的自发性心脏纤维化:一种罕见的突变揭示了一种常见的分子病理生理学
- 批准号:
10402774 - 财政年份:2019
- 资助金额:
$ 25.66万 - 项目类别:
Spontaneous cardiac fibrosis in PAI-1-deficient mice and men: A rare mutation informs a common molecular pathophysiology
PAI-1 缺陷小鼠和男性的自发性心脏纤维化:一种罕见的突变揭示了一种常见的分子病理生理学
- 批准号:
9908161 - 财政年份:2019
- 资助金额:
$ 25.66万 - 项目类别:
DEFINING STRATEGIES FOR IMPROVING ENDOTHELIAL/FIBRINOLYTIC DYFUNCTION IN OBESITY
制定改善肥胖症内皮/纤溶功能障碍的策略
- 批准号:
7605664 - 财政年份:2006
- 资助金额:
$ 25.66万 - 项目类别:
相似海外基金
CORE--TRANSGENIC ANIMALS AND ATHEROSCLEROSIS MEASUREMENTS
核心——转基因动物和动脉粥样硬化测量
- 批准号:
6353520 - 财政年份:2000
- 资助金额:
$ 25.66万 - 项目类别:
CORE--TRANSGENIC ANIMALS AND ATHEROSCLEROSIS MEASUREMENTS
核心——转基因动物和动脉粥样硬化测量
- 批准号:
6202169 - 财政年份:1999
- 资助金额:
$ 25.66万 - 项目类别:
CORE--TRANSGENIC ANIMALS AND ATHEROSCLEROSIS MEASUREMENTS
核心——转基因动物和动脉粥样硬化测量
- 批准号:
6109433 - 财政年份:1998
- 资助金额:
$ 25.66万 - 项目类别:
Gene Regulation of Atherosclerosis in Diabetic Animals
糖尿病动物动脉粥样硬化的基因调控
- 批准号:
6948837 - 财政年份:1997
- 资助金额:
$ 25.66万 - 项目类别:
CORE--TRANSGENIC ANIMALS AND ATHEROSCLEROSIS MEASUREMENTS
核心——转基因动物和动脉粥样硬化测量
- 批准号:
6241568 - 财政年份:1997
- 资助金额:
$ 25.66万 - 项目类别:
Gene Regulation of Atherosclerosis in Diabetic Animals
糖尿病动物动脉粥样硬化的基因调控
- 批准号:
6543490 - 财政年份:1997
- 资助金额:
$ 25.66万 - 项目类别:
Gene Regulation of Atherosclerosis in Diabetic Animals
糖尿病动物动脉粥样硬化的基因调控
- 批准号:
6654928 - 财政年份:1997
- 资助金额:
$ 25.66万 - 项目类别:
Gene Regulation of Atherosclerosis in Diabetic Animals
糖尿病动物动脉粥样硬化的基因调控
- 批准号:
6784143 - 财政年份:1997
- 资助金额:
$ 25.66万 - 项目类别:
SMOOTH MATRICES AS A MODEL FOR INJURY IN ATHEROSCLEROSIS /HUMAN,ANIMALS
平滑基质作为动脉粥样硬化损伤模型/人类、动物
- 批准号:
3920329 - 财政年份:
- 资助金额:
$ 25.66万 - 项目类别:
SMOOTH MATRICES AS A MODEL FOR INJURY IN ATHEROSCLEROSIS /HUMAN,ANIMALS
平滑基质作为动脉粥样硬化损伤模型/人类、动物
- 批准号:
3943102 - 财政年份:
- 资助金额:
$ 25.66万 - 项目类别:














{{item.name}}会员




